XNCR

Over the past six months, Xencor's stock price has shown an upward trend, increasing by 60.9% since the beginning of 2026 and 97.6% over the past year. Key events include a 16.9% stock increase on July 17, 2026, following an announcement of a presentation for XmAb819 data at ESMO 2026. On July 29, 2026, the stock rose 10.04% after Xencor announced a $105 million settlement with Alexion regarding Ultomiris® royalties. The company's Q2 2026 financial results, reported on August 5, 2026, showed a reduced net loss and beat revenue estimates, positively impacting the stock. Other notable events include Xencor's presentation at the 2026 Cantor Global Healthcare Conference on September 2, 2026, Bank of America adjusting its price target to $26 on September 21, 2026, and Wedbush indicating on September 25, 2026, that XmAb819 data could support a registrational path. In September 2026, shares crossed the average analyst target price of $29.00, and in October 2026, news emerged about better funding for Obexelimab and analyst coverage by Wells Fargo & Company. Earlier, in May 2026, Q1 earnings missed analyst expectations, and in April 2026, a 2.7% increase in shares outstanding was noted as a minor dilution risk.